Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joi... (00mg oral dose of linezolid given twiced...)

HOME >> MEDICINE >> TECHNOLOGY

Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting

Date:10/26/2008

00mg oral dose of linezolid given twice daily for five to ten days in the treatment of ambulatory patients with uSSSI where incision and drainage would not be sufficient therapy. It also sought to evaluate the safety and tolerability profile of these two doses compared to linezolid.

About Uncomplicated Skin and Soft Tissue Infections (uSSSI)

Uncomplicated skin and skin structure infection (uSSSI) is a term used to group a wide range of bacterial skin infections, including common dermatologic diseases such as cellulitis, carbuncles and impetigo. These infections may result from minor skin abrasions or even insect bites. The most common cause of uSSSIs is the bacterial Group A streptococci and S. aureus.

About Radezolid

Radezolid is a novel oxazolidinone that was discovered using Rib-X's proprietary discovery process and was designed to expand the bacterial spectrum and improve the utility of this class of antibiotics relative to the only other oxazolidinone marketed in the world, Zyvox(R) (linezolid). Rib-X is developing both oral and IV formulations for use in serious hospital Gram-positive infections, including those caused by MRSA and linezolid- and vancomycin-resistant enterococci. Radezolid is the subject of a second ongoing Phase 2 clinical trial for community acquired pneumonia (CAP). This compound has been shown to be microbiologically more active than linezolid against Gram-positive organisms, including potent activity against linezolid resistant bacteria, in prior studies.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effe
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India

Post Your Comments:

Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joi...(00mg oral dose of linezolid given twiced...),Health